Shaker A. Mousa - Concepedia

Author

Shaker A. Mousa

Albany College of Pharmacy and Health Sciences ORCID

Also Known As

Joel Bennett, Mousa, Mousa SA, Mousa, A.S., Mousa, S., Mousa, S.A., Mousa, Shaker A, Mousa,S. A., Mousa,Shaker, Mousa,Shaker A

972

Publications

33.3K

Citations

H-Index

325

Concepts

All Affiliations

Albany College of Pharmacy and Health Sciences Wilmington University DuPont (United States)Albany Medical Center Hospital King Abdulaziz University

About

Shaker A. Mousa is an author at Albany College of Pharmacy and Health Sciences specializing in medicine, pharmacology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	54	180	10.4K
2	Health Sciences	24	33	1.9K
3	Engineering	23	27	1.8K
4	Natural Sciences	16	22	1.3K
5	Public Health	5	5	87

Shaker A. Mousa

342

Publications

18.6K

Citations

H-Index

Page 1

	Year	Citations
Regulation of Angiogenesis in Vivo by Ligation of Integrin α5β1 with the Central Cell-Binding Domain of Fibronectin Semi Kim, K.S. Bell, Shaker A. Mousa, American Journal Of Pathology AngiogenesisSignal TransductionCell SignalingImmunologyCell-matrix Interaction	2000	624
Integrin αVβ3 Contains a Cell Surface Receptor Site for Thyroid Hormone that Is Linked to Activation of Mitogen-Activated Protein Kinase and Induction of Angiogenesis Joel J. Bergh, Hung‐Yun Lin, Lawrence Lansing, Endocrinology ImmunologyPlasma Membrane AlphaAngiogenesisCell Surface ReceptorSignaling Pathway	2005	566
Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Zhong Chen, P. S. Malhotra, Giovana R. Thomas, PubMed Neck CancerImmunologyImmune RegulationPathologyImmunotherapy	1999	487
Chemoenzymatic Synthesis of Homogeneous Ultralow Molecular Weight Heparins Yongmei Xu, Sayaka Masuko, Majde Takieddin, Science Chemoenzymatic SynthesisPharmaceutical ScienceGlycobiologyEnzymatic ModificationPharmaceutical Chemistry	2011	393
Introducing Nanochemoprevention as a Novel Approach for Cancer Control: Proof of Principle with Green Tea Polyphenol Epigallocatechin-3-Gallate Imtiaz A. Siddiqui, Vaqar M. Adhami, Dhruba J. Bharali, Cancer Research NanomedicineHealth SciencesChemoprevention StrategyPolymer-drug ConjugateMedicine	2009	376
Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library Karyn T. O’Neil, Ronald H. Hoess, Sharon Jackson, Proteins Structure Function and Bioinformatics	1992	280
<scp>l</scp>-Thyroxine vs. 3,5,3′-triiodo-<scp>l</scp>-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase Hung‐Yun Lin, Mingzeng Sun, Heng-Yuan Tang, American Journal of Physiology-Cell Physiology Src KinaseCell ProliferationGliomaNeuro-oncologySignaling Pathway	2009	248
Proangiogenic Action of Thyroid Hormone Is Fibroblast Growth Factor–Dependent and Is Initiated at the Cell Surface Faith B. Davis, Shaker A. Mousa, Laura O’Connor, Circulation Research Endothelial CellsAngiogenesisCell SurfaceFibroblast Growth FactorCell Signaling	2004	223
Synthesis of Gold and Silver Nanoparticles Stabilized with Glycosaminoglycans Having Distinctive Biological Activities Melissa M. Kemp, Ashavani Kumar, Shaymaa Mousa, Biomacromolecules	2009	212
Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model Naghma Khan, Dhruba J. Bharali, Vaqar M. Adhami, Carcinogenesis NanoparticlesNanomedicinePolyphenolicsEngineeringPolymer-drug Conjugate	2013	207

Page 1